Navigation Links
Champions Oncology Clarifies Misstatements in News Article
Date:7/18/2011

BALTIMORE, July 18, 2011 /PRNewswire/ -- Champions Oncology, Inc., formerly Champions Biotechnology, Inc. (OTC: CSBR) released the following statement to correct errors which recently appeared in Hebrew in the Israeli biotechnology business press and which came to the Company's attention on July 16, 2011:

"Recently, a Hebrew language business news service reported that Champions has agreed to create a subsidiary which will be used by Champions for the development of a drug compound that we have in-licensed.  Contrary to this news report, the Company has not made any final determination with respect to the future development of this drug compound."

As the Company stated in our Annual Report on Form 10-K for our fiscal year ended April 30, 2011 (filed on July 15, 2011):

Historically, our strategy was to use our technology platform to identify promising compounds that could be in-licensed during the preclinical phase.  The strategy was to invest in the clinical development of these compounds and then seek a partner that would bring them to market in exchange for some combination of upfront payments, milestone payments and royalties on sales.  Since 2007, the company pursued this strategy with four compounds.  All four of these compounds were subjected to Tumorgraft testing, and the results of one of the compounds warranted further investment.  During 2011, we changed our strategy and no longer intend to in-license additional compounds.  We have refocused the Company on developing advanced technologies to personalize the development and use of oncology drugs.  We intend to continue the development of the compound which warranted further investment and we are seeking a partner to finance the future development of the product.

We are working to assess potential financing alternatives for developing this compound, including the appropriate structure and valuation.  We do not yet have the information nee
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Champions Oncology Reports Full Year 2011 Financial Results
2. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
3. Champions Biotechnology Changes Name to Champions Oncology
4. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
5. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
6. Champions Biotechnology Reports Additions to its Management Team
7. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
8. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
9. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
10. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
11. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
(Date:12/15/2014)... 2014 Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology,  today celebrated continued ... its exVive3D TM Human Liver Tissue.  The ... commercial release on November 18, has been recognized ... awards for innovation. Most recently, on ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
(Date:12/13/2014)... Clarassance, a privately held clinical-stage biotechnology ... Therabron Therapeutics , Inc. The new name is ... of structure in the lungs similar to branches on ... novel protein therapeutics for the treatment of respiratory diseases. ... the name to mark the company's escalation into the ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... exhibit to open Thursday , Madison, Wis. ... exhibit on advances in nanotechnology, run by the university and ... p.m. on December 16 during a campus open house, with ... science fiction as the manufacture of tiny robots, has led ...
... opening passages of Alice in Wonderland , you should. ... accurate description of most modern IT projects. , ,The business-like ... always just out of reach around the next turn of ... dialog. The falling, tumbling, almost hallucinogenic quality of a workload ...
... the highway reconstruction efforts continue their development in downtown Milwaukee, ... spent on a Web site that will update people on ... Marquette Interchange Project was established in September by the ... on the interchange, HNTP and CH2M Hill ...
Cached Biology Technology:Tech Digest: Nanotechnology, GE Healthcare, NovaMed, PhysioGenix 2The IT drug Just say no? 2The IT drug Just say no? 3$685,000 too much for construction Web site, critics say 2$685,000 too much for construction Web site, critics say 3
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... farmers worldwide to plant genetically modified (GM) cotton to ... several years by saving on pesticides have now been ... researchers at the American Agricultural Economics Association (AAEA) Annual ... that other pests are now attacking the GM cotton. ...
... after the end-Cretaceous mass extinction was much more chaotic ... shows that at certain times and places, plant and ... as they are today. The extinction took place 65.5 ... the beginning of the Cenozoic Era and the Paleocene ...
... five major food crops grown under carbon-dioxide levels ... bounty than those raised in earlier greenhouse and ... global food supplies could be at risk without ... are based on on-going open-air research at the ...
Cached Biology News:Bt cotton in China fails to reap profit after seven years 2Insect predation sheds light on food web recovery after the dinosaur extinction 2Insect predation sheds light on food web recovery after the dinosaur extinction 3Insect predation sheds light on food web recovery after the dinosaur extinction 4Food-crop yields in future greenhouse-gas conditions lower than expected 2